z-logo
open-access-imgOpen Access
The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study
Author(s) -
Mobina Fathi,
Kimia Vakili,
Fatemeh Sayehmiri,
Ashraf Mohamadkhani,
Mohammadreza Hajiesmaeili,
Mostafa RezaeiTavirani,
Owrang Eilami
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0246190
Subject(s) - medicine , comorbidity , meta analysis , myalgia , medline , covid-19 , diabetes mellitus , web of science , disease , infectious disease (medical specialty) , political science , law , endocrinology
Background and objectives With the increase in the number of COVID-19 infections, the global health apparatus is facing insufficient resources. The main objective of the current study is to provide additional data regarding the clinical characteristics of the patients diagnosed with COVID-19, and in particular to analyze the factors associated with disease severity, lack of improvement, and mortality. Methods 102 studies were included in the present meta-analysis, all of which were published before September 24, 2020. The studies were found by searching a number of databases, including Scopus, MEDLINE, Web of Science, and Embase. We performed a thorough search from early February until September 24. The selected papers were evaluated and analyzed using Stata software application version 14. Results Ultimately, 102 papers were selected for this meta- analysis, covering 121,437 infected patients. The mean age of the patients was 58.42 years. The results indicate a prevalence of 79.26% for fever (95% CI: 74.98–83.26; I 2 = 97.35%), 60.70% for cough (95% CI: 56.91–64.43; I 2 = 94.98%), 33.21% for fatigue or myalgia (95% CI: 28.86–37.70; I 2 = 96.12%), 31.30% for dyspnea (95% CI: 26.14–36.69; I 2 = 97.67%), and 10.65% for diarrhea (95% CI: 8.26–13.27; I 2 = 94.20%). The prevalence for the most common comorbidities was 28.30% for hypertension (95% CI: 23.66–33.18; I 2 = 99.58%), 14.29% for diabetes (95% CI: 11.88–16.87; I 2 = 99.10%), 12.30% for cardiovascular diseases (95% CI: 9.59–15.27; I 2 = 99.33%), and 5.19% for chronic kidney disease (95% CI: 3.95–6.58; I 2 = 96.42%). Conclusions We evaluated the prevalence of some of the most important comorbidities in COVID-19 patients, indicating that some underlying disorders, including hypertension, diabetes, cardiovascular diseases, and chronic kidney disease, can be considered as risk factors for patients with COVID-19 infection. Furthermore, the results show that an elderly male with underlying diseases is more likely to have severe COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom